Drugs / Pictilisib
Pictilisib
English name pictilisib
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 112 trials | ||||||
| Phase 1 | NCT02389842 | Mar 2015 → Oct 2018 | breast cancer | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT02092831 | Apr → May 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01474668 | Oct 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01240226 | Nov → Dec 2010 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00996892 | Nov 2009 → Mar 2014 | cancer | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00999128 | Oct 2009 → Feb 2010 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00974584 | Oct 2009 → Mar 2015 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00975182 | Sep 2009 → Sep 2014 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00960960 | Aug 2009 → Dec 2015 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00928330 | Jul 2009 → Jan 2014 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00876122 | Mar 2008 → Jun 2012 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00876109 | Oct 2007 → Jun 2012 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01918306 | Sep 2013 → Dec 2014 | triple-negative breast carcinoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02430363 | Mar 2013 → Jan 2016 | glioblastoma | Medical Research Council | Unknown | No outcome recorded |
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT01740336 | Feb 2013 → Oct 2015 | breast cancer | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01493843 | Jan 2012 → Mar 2016 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01437566 | Oct 2011 → Apr 2016 | breast cancer | Genentech, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-04-10 | AbbVie | Results ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting abbvie.com ↗
Enhanced in vitro and in vivo activity of trastuzumab-DM1 antibody-drug conjugate combined with GDC-0941, a small molecule inhibitor of PI3 kinase |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-04-10 | AbbVie | ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting abbvie.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pictilisib | “A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF FORMULATION AND TABLET HARDNESS ON THE RELATIVE BIOAVAILABILITY OF PICTILISIB (GDC-0941) IN HEALTHY SUBJECTS” NCT02092831 ↗5“Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ.” NCT02430363 ↗ |
| Known as | CDC-0941 | ChEMBL registry synonym — accepted as the source's own label CHEMBL521851 ↗ |
| Known as | GDC-0941 | “oral (PO) GDC 0941 administered in combination with either intravenous (IV) infusion of T-DM1 or IV infusion of trastuzumab.” NCT00928330 ↗13“PI3K inhibitor GDC-0941 orally (PO) once daily (QD) on days 2-6, 9-13, 16-20, and 23-27.” NCT01918306 ↗ “Pictilisib (GDC-0941)” NCT02389842 ↗ |
| Known as | PICTILISIB (GDC-0941) | ChEMBL registry synonym — accepted as the source's own label CHEMBL521851 ↗ |
| Known as | PICTRELISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL521851 ↗ |
| Known as | RG-7321 | ChEMBL registry synonym — accepted as the source's own label CHEMBL521851 ↗ |
| Action | Inhibit | “PI3-Kinase Inhibitor (GDC-0941)” NCT00876122 ↗ |
| Modality | Small molecule | — CHEMBL521851 ↗ |
| Route | Oral | “administered in escalating oral doses” NCT00876109 ↗ |